Section Edited by Howard L. Kaufman, MD, FACS
This section focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Research describing the characterization and basic biology of oncolytic agents and novel delivery systems are encouraged. An emphasis on how novel intra-tumoral directed agents modulate local and systemic host innate and adaptive anti-tumor immunity are of particular interest. In addition, the section welcomes translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens.
Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumorsYu-Chao Zhu, Hany M Elsheikha, Jian-Hua Wang, Shuai Fang, Jun-Jun He, Xing-Quan Zhu, Jia Chen
1 November 2021
Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunityShunichi Taki, Kohei Matsuoka, Yuko Nishinaga, Kazuomi Takahashi, Hirotoshi Yasui, Chiaki Koike, Misae Shimizu, Mitsuo Sato, Kazuhide Sato
1 November 2021
Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinomaVictoria M Leb-Reichl, Melanie Kienzl, Anna Kaufmann, Angelika Stoecklinger, Birgit Tockner, Sophie Kitzmueller, Nadja Zaborsky, Markus Steiner, Gabriele Brachtl, Lisa Trattner, Patrick Kreideweiss, Christian Reinsch, Steffen Panzner, Richard Greil, Dirk StrunkSee the full list of authors
21 October 2021
Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapyMohammed G Ghonime, Uksha Saini, Michael C Kelly, Justin C Roth, Pin-Yi Wang, Chun-Yu Chen, Katherine Miller, Ilse Hernandez-Aguirre, Yeaseul Kim, Xiaokui Mo, Joseph R Stanek, Tim Cripe, Elaine Mardis, Kevin A Cassady
1 October 2021
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironmentsMaulasri Bhatta, Gautam N Shenoy, Jenni L Loyall, Brian D Gray, Meghana Bapardekar, Alexis Conway, Hans Minderman, Raymond J Kelleher Jr, Beatriz M Carreno, Gerald Linette, Leonard D Shultz, Kunle Odunsi, Sathy V Balu-Iyer, Koon Yan Pak, Richard B Bankert
1 October 2021
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vacciniaWeiyi Wang, Shuaitong Liu, Peihong Dai, Ning Yang, Yi Wang, Rachel A Giese, Taha Merghoub, Jedd Wolchok, Liang Deng
30 September 2021
Simple and effective bacterial-based intratumoral cancer immunotherapyChristina S E Carroll, Erin R Andrew, Laeeq Malik, Kathryn F Elliott, Moira Brennan, James Meyer, Alexander Hintze, Andrew A Almonte, Cassandra Lappin, Philip MacPherson, Klaus-Martin Schulte, Jane E Dahlstrom, Rohit Tamhane, Teresa Neeman, Elizabeth W HerbertSee the full list of authors
16 September 2021
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunityClément Anfray, Francesco Mainini, Elisabeth Digifico, Akihiro Maeda, Marina Sironi, Marco Erreni, Achille Anselmo, Aldo Ummarino, Sara Gandoy, Francisco Expósito, Miriam Redrado, Diego Serrano, Alfonso Calvo, Marvin Martens, Susana BravoSee the full list of authors
16 September 2021
Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse modelHyein Jeong, So-Young Lee, Hyejun Seo, Bum-Joon Kim
13 August 2021
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoidsFiras Hamdan, Erkko Ylösmäki, Jacopo Chiaro, Yvonne Giannoula, Maeve Long, Manlio Fusciello, Sara Feola, Beatriz Martins, Michaela Feodoroff, Gabriella Antignani, Salvatore Russo, Otto Kari, Moon Hee Lee, Petrus Järvinen, Harry NisenSee the full list of authors
6 August 2021